{
    "clinical_study": {
        "@rank": "28498", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single arm study will evaluate the efficacy and safety of RoActemra/Actemra\n      (tocilizumab) in patients with rheumatoid arthritis. Patients will receive RoActemra/Actemra\n      8 mg/kg intravenously every 4 weeks, alone or in combination with standard anti-rheumatic\n      therapy, for 12 weeks."
        }, 
        "brief_title": "A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)", 
        "completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Confirmed moderate or severe rheumatoid arthritis\n\n          -  Intolerability or absence of effect or decrease in effect of rheumatoid arthritis\n             treatment with DMARDs\n\n        Exclusion Criteria:\n\n          -  Presence of infectious diseases (Tb, HIV, virus hepatitis A/B/C)\n\n          -  Inadequate hematologic, renal or liver function\n\n          -  Peptic ulcer disease (in acute phase)\n\n          -  Pregnant and lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010216", 
            "org_study_id": "ML23037"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "8 mg/kg by intravenous infusion every 4 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Almaty", 
                        "country": "Kazakhstan", 
                        "zip": "050000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Astana", 
                        "country": "Kazakhstan", 
                        "zip": "010000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Astana", 
                        "country": "Kazakhstan", 
                        "zip": "010009"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shymkent", 
                        "country": "Kazakhstan", 
                        "zip": "160000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shymkent", 
                        "country": "Kazakhstan", 
                        "zip": "160006"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ust-kamenogorsk", 
                        "country": "Kazakhstan", 
                        "zip": "070002"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Kazakhstan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Non-Randomized Phase IV Trial on Efficacy and Safety of Actemra in the Treatment of Adult Patients With Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Kazakh: Pharmacy Committee of Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in disease activity DAS28 score", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 12"
            }, 
            {
                "measure": "Proportion of patients achieving ACR20/50/70", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010216"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}